Anti–miR-17 treatment alleviates skin damage in a sclerodermatous cGVHD model. BALB/c mice were lethally irradiated and transferred with 5 × 10⁶ TCD-BM plus 5 × 10⁶ splenocytes from B10.D2 mice. Recipient mice were treated with anti–miR-17 or scrambled at a loading dose 25 mg/kg at day 0 followed by 5 mg/kg twice weekly up to day 25 after BMT. (A) The clinical scores of the recipient skin with macroscopic photos are shown 45 days after BMT. Pathology scores (B) and H&E staining (original magnification ×200) (C) in recipient skin are shown at 60 days after BMT. Representative flow figures (D) and average numbers (E) of IL-17⁺ cells on gated donor Ly9.1⁻CD4⁺ live cells in skin draining lymph nodes are shown at day 60 after BMT. N = 7 mice per group. *P < .05; ***P < .001.